Hypofunction of macrophage chemotaxis contributes to defective efficacy of herceptin in HER2-positive breast cancer patients
Breast cancer was considered as a kind of prone breast tumors with the complicated pathological mechanisms and diverse clinical classifications. In the clinical treatments of HER2-positive tumor patients, HER2 monoclonal antibodies, such as Herceptin, have shown well-defined therapeutic effects. Nev...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Molecular & Cellular Oncology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/23723556.2024.2309715 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850248091930722304 |
|---|---|
| author | Yu Song Qiao-Chen Geng Wen-Jing An Fu-Cheng Zhang Ran Jiang Rui-Sheng Zhao Zhi-Jian Deng Heng Li |
| author_facet | Yu Song Qiao-Chen Geng Wen-Jing An Fu-Cheng Zhang Ran Jiang Rui-Sheng Zhao Zhi-Jian Deng Heng Li |
| author_sort | Yu Song |
| collection | DOAJ |
| description | Breast cancer was considered as a kind of prone breast tumors with the complicated pathological mechanisms and diverse clinical classifications. In the clinical treatments of HER2-positive tumor patients, HER2 monoclonal antibodies, such as Herceptin, have shown well-defined therapeutic effects. Nevertheless, due to the heterogeneity of breast cancers, drug resistance inevitably appeared during the application of Herceptin. In order to fully understand the immune tolerance status of the tumor microenvironment in the population of sensitive and insensitive patients, this study carried out a series of studies through Luminex cytokines assay, clinicopathological analysis, immunofluorescence, and PCR. The results confirmed that in clinical samples sensitive to Herceptin, there were a large number of macrophages, and the protein expression levels and in situ expression of macrophage-related chemokines and inflammatory mediators are significantly higher than drug-resistant tumor samples. Further studies found that T cell function has a low correlation with tumor growth, and there are obvious obstacles in the process of peripheral blood immune cells entering the tumor microenvironment. In summary, this study provided clues for understanding the clinical drug resistance of HER2 monoclonal antibody and the clinical rational use of drugs and combination drugs. |
| format | Article |
| id | doaj-art-26eb539acf5e45d59c9da63d01489be6 |
| institution | OA Journals |
| issn | 2372-3556 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Molecular & Cellular Oncology |
| spelling | doaj-art-26eb539acf5e45d59c9da63d01489be62025-08-20T01:58:48ZengTaylor & Francis GroupMolecular & Cellular Oncology2372-35562024-12-0111110.1080/23723556.2024.2309715Hypofunction of macrophage chemotaxis contributes to defective efficacy of herceptin in HER2-positive breast cancer patientsYu Song0Qiao-Chen Geng1Wen-Jing An2Fu-Cheng Zhang3Ran Jiang4Rui-Sheng Zhao5Zhi-Jian Deng6Heng Li7College of Pharmacy, Xinxiang Medical University, Xinxiang, ChinaCollege of Pharmacy, Xinxiang Medical University, Xinxiang, ChinaCollege of Pharmacy, Xinxiang Medical University, Xinxiang, ChinaCollege of Pharmacy, Xinxiang Medical University, Xinxiang, ChinaCollege of Pharmacy, Xinxiang Medical University, Xinxiang, ChinaCollege of Pharmacy, Xinxiang Medical University, Xinxiang, ChinaCollege of Pharmacy, Xinxiang Medical University, Xinxiang, ChinaYong Loo Lin School of Medicine, National University of Singapore, Singapore, SingaporeBreast cancer was considered as a kind of prone breast tumors with the complicated pathological mechanisms and diverse clinical classifications. In the clinical treatments of HER2-positive tumor patients, HER2 monoclonal antibodies, such as Herceptin, have shown well-defined therapeutic effects. Nevertheless, due to the heterogeneity of breast cancers, drug resistance inevitably appeared during the application of Herceptin. In order to fully understand the immune tolerance status of the tumor microenvironment in the population of sensitive and insensitive patients, this study carried out a series of studies through Luminex cytokines assay, clinicopathological analysis, immunofluorescence, and PCR. The results confirmed that in clinical samples sensitive to Herceptin, there were a large number of macrophages, and the protein expression levels and in situ expression of macrophage-related chemokines and inflammatory mediators are significantly higher than drug-resistant tumor samples. Further studies found that T cell function has a low correlation with tumor growth, and there are obvious obstacles in the process of peripheral blood immune cells entering the tumor microenvironment. In summary, this study provided clues for understanding the clinical drug resistance of HER2 monoclonal antibody and the clinical rational use of drugs and combination drugs.https://www.tandfonline.com/doi/10.1080/23723556.2024.2309715Herceptinbreast cancermacrophageschemotaxis |
| spellingShingle | Yu Song Qiao-Chen Geng Wen-Jing An Fu-Cheng Zhang Ran Jiang Rui-Sheng Zhao Zhi-Jian Deng Heng Li Hypofunction of macrophage chemotaxis contributes to defective efficacy of herceptin in HER2-positive breast cancer patients Molecular & Cellular Oncology Herceptin breast cancer macrophages chemotaxis |
| title | Hypofunction of macrophage chemotaxis contributes to defective efficacy of herceptin in HER2-positive breast cancer patients |
| title_full | Hypofunction of macrophage chemotaxis contributes to defective efficacy of herceptin in HER2-positive breast cancer patients |
| title_fullStr | Hypofunction of macrophage chemotaxis contributes to defective efficacy of herceptin in HER2-positive breast cancer patients |
| title_full_unstemmed | Hypofunction of macrophage chemotaxis contributes to defective efficacy of herceptin in HER2-positive breast cancer patients |
| title_short | Hypofunction of macrophage chemotaxis contributes to defective efficacy of herceptin in HER2-positive breast cancer patients |
| title_sort | hypofunction of macrophage chemotaxis contributes to defective efficacy of herceptin in her2 positive breast cancer patients |
| topic | Herceptin breast cancer macrophages chemotaxis |
| url | https://www.tandfonline.com/doi/10.1080/23723556.2024.2309715 |
| work_keys_str_mv | AT yusong hypofunctionofmacrophagechemotaxiscontributestodefectiveefficacyofherceptininher2positivebreastcancerpatients AT qiaochengeng hypofunctionofmacrophagechemotaxiscontributestodefectiveefficacyofherceptininher2positivebreastcancerpatients AT wenjingan hypofunctionofmacrophagechemotaxiscontributestodefectiveefficacyofherceptininher2positivebreastcancerpatients AT fuchengzhang hypofunctionofmacrophagechemotaxiscontributestodefectiveefficacyofherceptininher2positivebreastcancerpatients AT ranjiang hypofunctionofmacrophagechemotaxiscontributestodefectiveefficacyofherceptininher2positivebreastcancerpatients AT ruishengzhao hypofunctionofmacrophagechemotaxiscontributestodefectiveefficacyofherceptininher2positivebreastcancerpatients AT zhijiandeng hypofunctionofmacrophagechemotaxiscontributestodefectiveefficacyofherceptininher2positivebreastcancerpatients AT hengli hypofunctionofmacrophagechemotaxiscontributestodefectiveefficacyofherceptininher2positivebreastcancerpatients |